Bone cancer surgery recovery tracked in new study
NCT ID NCT03442465
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 300 people who had surgery to remove bone tumors (like osteosarcoma or chondrosarcoma). Researchers want to see how well the bone heals and how much function returns over 3 years. Participants fill out questionnaires about their daily activities. No new drug or treatment is being tested—this is about understanding recovery after standard surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
-
Memorial Sloan Kettering Monmouth (Consent and Followup)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Westchester (Consent and Followup)
RECRUITINGHarrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge (Consent and Follow Up)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering at Nassau (Consent and Followup)
RECRUITINGUniondale, New York, 11553, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill stall advanced sarcomas?
- Smartwatch exercise plan aims to rebuild fitness in young cancer survivors
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Real-Time nerve monitoring during spine surgery could predict bladder and bowel function
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors